Retatrutide+ Tirzepatide – 60mg Blend
The Retatrutide + Tirzepatide complex is a groundbreaking research blend combining 20mg of Retatrutide (a Triple GIP/GLP-1/Glucagon receptor agonist) and 40mg of Tirzepatide (a Dual GIP/GLP-1 receptor agonist). This 60mg total concentration represents the apex of current metabolic pharmacology research. By integrating Retatrutide’s unique ability to engage the Glucagon receptor (GCGR) for thermogenesis and hepatic fat mobilization with Tirzepatide’s potent GHR and GLP-1 receptor synergy, this blend provides researchers with an unparalleled tool to study maximal energy expenditure, glucose homeostasis, and the mechanisms of non-linear fat oxidation.
Our Retatrutide + Tirzepatide blend is synthesized in an ISO 9001:2015 certified and GMP-grade manufacturing facility. Utilizing advanced co-lyophilization technology, we ensure both peptide chains are stabilized within a single vacuum-sealed vial. With a verified chemical purity of ≥99%, this complex is free from isomeric impurities and residual reagents, ensuring high-fidelity results for studies involving insulin sensitivity and visceral adipose tissue (VAT) remodeling.
Research Applications & Mechanisms
Triple vs. Dual Agonism Synergy
Investigating the potentiation of metabolic signaling when GLP-1 and GIP receptors are simultaneously stimulated alongside the Glucagon receptor.
Intensive Hepatic & Adipose Lipolysis
Researching the influence of the GCGR component in Retatrutide on liver fat oxidation and the subsequent systemic metabolic rate enhancement.
Glycemic Control & Insulin Sensitivity
Studying the dual-pathway mechanism of GIP and GLP-1 in optimizing postprandial glucose regulation and pancreatic beta-cell stability.
Satiety & Neuro-Metabolic Signaling
Exploring the combined effects of multiple incretin mimetics on the hypothalamic appetite centers and energy homeostasis.
Technical Specifications
| Parameter | Laboratory Standard |
| Components | Retatrutide (20mg) / Tirzepatide (40mg) |
| Total Concentration | 60mg per vial |
| Target Receptors | GLP-1R / GIPR / GCGR (Glucagon Receptor) |
| Purity (HPLC) | ≥99% (Pharmaceutical Grade) |
| Physical Appearance | Fine, Smooth & Flat Lyophilized Cake |
| Solubility | Highly Soluble in Water / Bacteriostatic Water |
| Batch Control | MS & HPLC Analysis Verified |
Key Features & Quality Assurance
Advanced Co-Lyophilization Technology
Our proprietary process ensures the Retatrutide + Tirzepatide powder surface is perfectly smooth, flat, and delicate. This uniform structure prevents premature molecular interaction and ensures identical reconstitution ratios across all research batches.
Multi-Sequence Integrity Verification
Every batch undergoes rigorous Mass Spectrometry (MS) to confirm the structural identity of both the 39-amino acid Tirzepatide sequence and the specialized Retatrutide structure, ensuring no loss of bioactivity.
Reconstitution & Storage
Reconstitution Guide
-
Preparation: Allow the vial to reach room temperature. Centrifuge for 30-60 seconds to ensure the lyophilized cake is at the base.
-
Solvent: Reconstitute with Sterile Water or Bacteriostatic Water.
-
Technique: Introduce the diluent gently against the vial wall. DO NOT SHAKE; swirl gently until the solution is clear and transparent.
Storage Protocols
-
Long-term: Store at -20°C (Maintains potency for up to 24 months).
-
Short-term: Stable at 2–8°C for up to 3 months.
-
Post-Reconstitution: Store at 2–8°C and utilize within 14-21 days.
Shipping & Documentation
-
Global Logistics: Shipped in discreet, temperature-controlled packaging to protect the sensitive Retatrutide & Tirzepatide sequences.
-
Verified Quality: A batch-specific Certificate of Analysis (COA) and HPLC/MS reports are available for every order.
-
Reshipment Policy: We provide a guaranteed reshipment policy for any lost or customs-intercepted orders (terms apply).
⚠️ Research Disclaimer
Product-Specific Safety Notice: This Retatrutide + Tirzepatide blend is strictly for laboratory research and analytical purposes. It is NOT intended for human or veterinary administration. All research must be conducted by qualified professionals in controlled environments.
Scientific Resources & References
-
National Center for Biotechnology Information (NCBI): Compound Summary – Retatrutide (LY3437943) & Tirzepatide (GLP-1/GIP dual agonist)
-
PubMed – NIH: Clinical research on Retatrutide (triple agonist: GLP-1/GIP/Glucagon) and Tirzepatide (GLP-1/GIP)
🔍 Deep Dive Research
-
[Technical Guide]: How to Reconstitute and Store Lyophilized Peptides for Maximum Potency
-
[Metabolic Study]: The Triple Agonist Frontier: Retatrutide and the Future of Lipolysis Research










wavestack –
Looks fine.